We have read with interest the recent papers of Kennedy et al 1 2 regarding the attenuated anti-SARS-CoV-2 antibody response in patients with IBD and the crucial role of the COVID-19 vaccine in this cohort. The COVID-19 vaccine has been recommended especially for the vulnerable population, including immune-mediated inflammatory diseases.3–5 Therefore, we explored the rate of adverse events (AEs) and the onset of GI symptoms after vaccination with different COVID-19 vaccines in a large cohort of patients with IBD. In this prospective study, we collected data (demographic and clinical variables, COVID-19 vaccine type, local, systemic or allergic AEs, and GI symptoms) from 488 (mean age±SD 55.3±14.4 years, 44.9% male) patients with IBD (UC 50.4%, Crohn’s disease 47.8% and undetermined IBD 1.8%) on regular follow-up at our IBD unit who had been administered COVID-19 vaccination from June to July 2021. The demographic characteristics are shown in table 1. AEs were reported by 228 patients (46.7%) (figure 1). The most common systemic AE after the first dose was malaise (16.4%), followed by headache (12.9%) and asthenia (10.5%). …

中文翻译：

---

IBD 患者接种 COVID-19 疫苗后的不良事件风险和报告的临床复发

我们感兴趣地阅读了 Kennedy 等人 1 2 最近关于 IBD 患者抗 SARS-CoV-2 抗体反应减弱以及 COVID-19 疫苗在该队列中的关键作用的论文。COVID-19 疫苗特别推荐用于弱势人群，包括免疫介导的炎症性疾病。3-5 因此，我们探讨了接种不同 COVID-19 疫苗后不良事件 (AE) 的发生率和胃肠道症状的发生率在一大群 IBD 患者中。在这项前瞻性研究中，我们收集了 488 名（平均年龄±SD 55.3±14.4 岁，44.9% 男性）IBD 患者的数据（人口统计学和临床​​变量、COVID-19 疫苗类型、局部、全身或过敏性 AE 和 GI 症状） （UC 50.4%，克罗恩病 47.8% 和未确定的 IBD 1。8%）在我们的 IBD 部门进行了定期随访，这些人于 2021 年 6 月至 7 月接受了 COVID-19 疫苗接种。人口统计学特征如表 1 所示。228 名患者（46.7%）报告了 AE（图 1）。首次给药后最常见的全身 AE 是不适（16.4%），其次是头痛（12.9%）和虚弱（10.5%）。…